Biovaxys Technology Corp (BVAXF)

$0.07 0.00 (-0.14%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 6,000
Avg Vol 27,068
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 34%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
FLArnot
FLArnot Sep. 2 at 8:48 PM
$BVAXF Their tweet is encouraging, but their statement "That is exactly where $BIOV $BVAXF and DPX is positioned." is not correct. DPX is positioned behind $BIOV $BVAXF , which is positioned behind non-regulatory penalty. So nothing moves on news, and value is frozen. I will consider it real news when the CTO is lifted, and Merck uses $BIOV $BVAXF in their tweet, not the other way around.
0 · Reply
ProfitWhisperer
ProfitWhisperer Sep. 2 at 4:28 PM
$BVAXF $BIOV.CSE Cancer vaccines entering new era on better antigens, better delivery, durable T-cell responses. Moderna/Merck Phase 3 proves the principle. BIOV already executing this thesis via PESCO study combining DPX + pembrolizumab. Platform positioned exactly where market is moving. https://x.com/biovaxys/status/2094871059204014382
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:18 PM
$BVAXF If management would show they cared about their investors by giving a reason/update for the unprecedented delay and CTO,(which is different than all the updated timelines they gave) I might change my mind. Until then, they give the air that they don't give a damn about investors.
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:09 PM
$BVAXF Bear reason #6: Any financing from here is a bloodbath — with 29 million shares out and a two-million-dollar cap, raising even one year of runway means printing shares at a scale that makes the current float look quaint, and the MCTO/CTO bars them from issuing securities to insiders and employees until the filings land, which narrows the list of people willing to write the check.
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:09 PM
$BVAXF Bear reason #5: The IMV assets were already tested by the market and failed the test — a well-funded company burned through nine figures on this exact platform and went bankrupt anyway, so "acquired at a fraction of validated value" is a thesis that assumes the bankruptcy auction mispriced assets nobody else bid up.
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:06 PM
$BVAXF Bear reason #4: A ~C$2–3M market cap against a ~C$6M annual net loss means the market isn't valuing the DPX portfolio at a discount, it's valuing the whole enterprise at less than half a year of the burn required to do anything with it. Revenue: none. Net loss (ttm): C$5.97M.
1 · Reply
FLArnot
FLArnot Sep. 1 at 5:05 PM
$BVAXF Bear reason #3: They keep missing their own do-over deadlines — the FY2025 filings were promised by April 28, 2026, then quietly repriced to May 30, 2026, which is exactly the kind of rolling slippage that usually means the auditor found something they don't love.
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:04 PM
$BVAXF Bear reason #2: The consolidation solved nothing — post-split the stock still sits around C$0.07 against a 52-week range of C$0.03 to C$0.41, so the reverse split didn't buy a re-rating, it just made the chart look less embarrassing on the way down.
1 · Reply
FLArnot
FLArnot Sep. 1 at 5:02 PM
$BVAXF Bear reason #1: The filing delinquency is a habit, not an accident — an OSC failure-to-file order and CSE suspension in May 2024, an MCTO in March 2025, and another MCTO/CTO in March/May 2026 means three straight years of a company that can't close its own books on time.
0 · Reply
ProfitWhisperer
ProfitWhisperer Sep. 1 at 4:22 PM
$BVAXF $BIOV.CSE September 30 is critical deadline for BioVaxys. Horizon/HIMV agreement requires ~$425K US raise to be completed by then. Micro amount relative to DPX platform value. Filing completion clears trading suspension simultaneously. Two biggest risks potentially resolved same month. September execution matters.
0 · Reply
Latest News on BVAXF
No data available.
FLArnot
FLArnot Sep. 2 at 8:48 PM
$BVAXF Their tweet is encouraging, but their statement "That is exactly where $BIOV $BVAXF and DPX is positioned." is not correct. DPX is positioned behind $BIOV $BVAXF , which is positioned behind non-regulatory penalty. So nothing moves on news, and value is frozen. I will consider it real news when the CTO is lifted, and Merck uses $BIOV $BVAXF in their tweet, not the other way around.
0 · Reply
ProfitWhisperer
ProfitWhisperer Sep. 2 at 4:28 PM
$BVAXF $BIOV.CSE Cancer vaccines entering new era on better antigens, better delivery, durable T-cell responses. Moderna/Merck Phase 3 proves the principle. BIOV already executing this thesis via PESCO study combining DPX + pembrolizumab. Platform positioned exactly where market is moving. https://x.com/biovaxys/status/2094871059204014382
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:18 PM
$BVAXF If management would show they cared about their investors by giving a reason/update for the unprecedented delay and CTO,(which is different than all the updated timelines they gave) I might change my mind. Until then, they give the air that they don't give a damn about investors.
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:09 PM
$BVAXF Bear reason #6: Any financing from here is a bloodbath — with 29 million shares out and a two-million-dollar cap, raising even one year of runway means printing shares at a scale that makes the current float look quaint, and the MCTO/CTO bars them from issuing securities to insiders and employees until the filings land, which narrows the list of people willing to write the check.
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:09 PM
$BVAXF Bear reason #5: The IMV assets were already tested by the market and failed the test — a well-funded company burned through nine figures on this exact platform and went bankrupt anyway, so "acquired at a fraction of validated value" is a thesis that assumes the bankruptcy auction mispriced assets nobody else bid up.
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:06 PM
$BVAXF Bear reason #4: A ~C$2–3M market cap against a ~C$6M annual net loss means the market isn't valuing the DPX portfolio at a discount, it's valuing the whole enterprise at less than half a year of the burn required to do anything with it. Revenue: none. Net loss (ttm): C$5.97M.
1 · Reply
FLArnot
FLArnot Sep. 1 at 5:05 PM
$BVAXF Bear reason #3: They keep missing their own do-over deadlines — the FY2025 filings were promised by April 28, 2026, then quietly repriced to May 30, 2026, which is exactly the kind of rolling slippage that usually means the auditor found something they don't love.
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:04 PM
$BVAXF Bear reason #2: The consolidation solved nothing — post-split the stock still sits around C$0.07 against a 52-week range of C$0.03 to C$0.41, so the reverse split didn't buy a re-rating, it just made the chart look less embarrassing on the way down.
1 · Reply
FLArnot
FLArnot Sep. 1 at 5:02 PM
$BVAXF Bear reason #1: The filing delinquency is a habit, not an accident — an OSC failure-to-file order and CSE suspension in May 2024, an MCTO in March 2025, and another MCTO/CTO in March/May 2026 means three straight years of a company that can't close its own books on time.
0 · Reply
ProfitWhisperer
ProfitWhisperer Sep. 1 at 4:22 PM
$BVAXF $BIOV.CSE September 30 is critical deadline for BioVaxys. Horizon/HIMV agreement requires ~$425K US raise to be completed by then. Micro amount relative to DPX platform value. Filing completion clears trading suspension simultaneously. Two biggest risks potentially resolved same month. September execution matters.
0 · Reply
Davidendz
Davidendz Sep. 1 at 3:45 PM
$BVAXF A few hundred thousand is maintenance money, not what a platform with ovarian, bladder, breast, and NMIBC data is worth. The value case is a partner writing a real check against that package.
0 · Reply
Davidendz
Davidendz Sep. 1 at 3:45 PM
$BVAXF Yeah, $425K is pocket change next to a multi-indication DPX file. That’s a deadline number, not a price tag.
0 · Reply
Davidendz
Davidendz Sep. 1 at 3:45 PM
$BVAXF DPX already showed durable immune responses and combo activity. If only ~$425K is left on a raise covenant, that just underlines how cheap the equity is versus the science.
0 · Reply
FLArnot
FLArnot Sep. 1 at 5:00 AM
$BVAXF Sept 10th, one year ago the 1 for 10 reverse split. Followed by more dilution with private offering, followed by stock price falling below what is was before reverse split, followed by neary 1/3 the year halted for non-compliance. Who is gas lighting who?
0 · Reply
FLArnot
FLArnot Aug. 31 at 6:21 PM
$BVAXF The market isn't waiting for the halt to be lifted to speak. They can trade on the US side and their speech there doesn't match the hype.
1 · Reply
wheresdannynow
wheresdannynow Aug. 31 at 4:25 PM
$BVAXF $BIOV.CSE Quiet on filings, yes.
0 · Reply
wheresdannynow
wheresdannynow Aug. 31 at 4:24 PM
$BVAXF $BIOV.CSE The last scientific file still stands: ovarian combo validation in May, ASCO abstract in April, and July outreach on DPX neoantigen formulations for acral melanoma.
0 · Reply
wheresdannynow
wheresdannynow Aug. 31 at 4:24 PM
$BVAXF Only newer items are July company posts on Moffitt neoantigens, a Dalhousie CDMRP submission, and Nairobi/KAVI DPX collaboration talk.
0 · Reply
wheresdannynow
wheresdannynow Aug. 31 at 4:24 PM
$BVAXF Latest check: still no FY2025 audit on SEDAR, CSE still suspended T2 from the May 6 halt, last MCTO note dated April 28.
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 31 at 4:04 PM
$BVAXF $BIOV.CSE DPX already produced published clinical signals in ovarian, bladder, breast, and NMIBC, plus ASCO abstract this year. Multi-indication platform validation independent of halt. When filing completes, market prices what's already proven.
0 · Reply
FLArnot
FLArnot Aug. 29 at 8:29 AM
$BVAXF I hope these pumpers are getting paid to pump. Then at least someone is making money off this stock.
1 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 28 at 5:53 PM
$BVAXF $BIOV.CSE MCTO, CTO, filing delays are regulatory/administrative friction. Meanwhile, DPX keeps earning credibility independently. Merck partnership active, Sona executing melanoma combination studies, clinical work rolling. Platform execution doesn't pause for halt calendars.
0 · Reply